Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (REFALS)

Diagnosis ALS
Study phase Active
Participating centres UMC Utrecht

A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multi-center study in patients with Amyotrophic Lateral Sclerosis (ALS).

This study is to assess the effect of levosimendan versus placebo on respiratory function in patients with ALS.

Overall enrolment: 450 patients

Centres: 34 sites in the US, 5 sites in Australia, 7 sites in Canada, 2 sites in Austria, 3 sites in Belgium, 3 sites in Finland, 5 sites in Germany, 1 site in Italy, 5 sites in Spain, 3 sites in Sweden, 1 site in Ireland, 3 sites in The United Kingdom and 2 sites in The Netherlands (UMCU and AMC)

Read more on clinicaltrialsregister.eu Read more on clinicaltrials.gov